Furic

Quick links to important sections

Furic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Furic

Quick Facts

Property Description
Active Ingredient Febuxostat (INN)
Form Tablet (Oral dosage form)
Pharmacological Class Xanthine Oxidase Inhibitor
Common Use Urate-lowering therapy (ULT)
Origin Synthetic compound

What Type of Medication is Furic?

Furic is a synthetic, prescription-only medication whose active component is Febuxostat (INN). It is structurally classified as a non-purine selective inhibitor of xanthine oxidase. This classification means its primary function is to block the enzyme responsible for creating uric acid in the body. The drug is distinct from older agents, providing a chemically unique approach to managing elevated urate levels. The drug serves as an agent for lowering and maintaining serum urate concentrations in adults with hyperuricemia. This indicates that the medicine is clinically recognized for achieving the main therapeutic goal of reducing urate levels, a strategy essential for chronic hyperuricemia management.

Febuxostat: A Synthetic, Oral Tablet

Furic's active ingredient is Febuxostat, a pure synthetic compound manufactured as a single-ingredient product. It is provided as an oral dosage form, specifically a tablet, which is the intended route of administration for systemic action. Febuxostat provides a potent, non-purine option for patients requiring consistent control of urate levels. The tablet form and its synthetic origin underline the drug's positioning as a modern, targeted pharmaceutical tool for long-term management.

The General Purpose of Urate-Lowering Therapy

The general purpose of Furic is to achieve a sustained reduction in serum urate levels as part of urate-lowering therapy (ULT). The core mechanism involves inhibiting the activity of the xanthine oxidase (XO) enzyme. By blocking this enzyme, Febuxostat effectively reduces the overall production of uric acid, controlling the amount of circulating urate in the body. This approach provides a foundational strategy for addressing the primary underlying cause of elevated urate concentration, a scenario commonly targeted in adult patient groups. This mechanism serves as a way to maintain urate concentrations within a healthy, non-crystalline range.

What side effects are possible with Furic?

Possible Side Effects and Safety Information

The official safety information for Furic (Febuxostat) classifies possible side effects primarily by frequency and affected organ system, based on clinical trial data and post-marketing surveillance. This structure allows for a clear understanding of the medicine’s risk profile.


Adverse Reaction Classification

Classification Examples of Reactions
Common (1% to <10%) Gout flares (often at initiation), liver function abnormalities, nausea, headache, diarrhea.
Uncommon (0.1% to <1%) Dizziness, somnolence, abdominal pain, joint pain (arthralgia), muscle spasms, edema, and certain cardiovascular-related effects like palpitations.
Rare (<0.1%) Serious skin and hypersensitivity reactions (e.g., SJS, DRESS), fatal hepatic failure, pancreatitis, and anaphylaxis.

Serious Adverse Reactions and Key Safety Constraints

The label documents serious adverse reactions, notably a warning regarding a higher rate of cardiovascular death observed in patients with established major cardiovascular disease compared to allopurinol. Severe hypersensitivity reactions and cases of fatal hepatic failure have also been reported.

Safety notes specify that gout flares are frequently observed at the initiation of therapy due to changes in urate levels. The medication is contraindicated for use with concomitant mercaptopurine or azathioprine due to potential severe toxicity. The safety profile also includes constraints for patients with pre-existing major cardiovascular disease and those with severe renal or hepatic impairment, defining specific population considerations documented in regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents indicate that there is no clinical experience with acute overdose of Furic (Febuxostat), and specific acute manifestations or signs of overdose are not formally documented in prescribing information. Clinical studies using doses up to 300 mg per day for a short period in healthy subjects observed no dose-limiting toxicities.

Management for any suspected overdose event is officially limited to symptomatic and supportive treatment, as no specific antidote is known for Febuxostat. There is no official regulatory statement confirming the effectiveness of dialysis procedures in removing the medication from the body.

Required Emergency Actions

Immediate emergency medical attention is mandated when a suspected overdose occurs. Furthermore, regulators specifically require patients to seek immediate medical help if they experience symptoms related to the drug's overall serious risks, which include potential cardiovascular and cerebrovascular events. This requirement applies to symptoms such as:

  • Chest pain or shortness of breath
  • Rapid or irregular heartbeat
  • Numbness or weakness on one side of the body
  • Trouble talking or a sudden severe headache

Hospital monitoring may be required to manage any potential systemic effects following the ingestion of an excessive amount of the medication, consistent with the need to seek urgent professional medical evaluation.

Therapeutic Uses of Furic

What Furic Treats: Main Uses and Benefits

Furic is used to provide essential symptomatic relief and supportive assistance in managing specific health challenges, focusing primarily on acute and recurring episodes of significant discomfort. This medication is commonly used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed. It is considered relevant for conditions presenting with systemic or localized discomfort, particularly those involving inflammatory or irritative states and episodic or fluctuating manifestations.


Key Therapeutic Focus

Furic is applied when symptoms associated with acute or episodic changes intensify and create noticeable interference with daily stability. It is used across domains where short-term symptomatic assistance is appropriate, particularly for addressing symptom clusters that may become intense or disruptive and create noticeable functional strain or discomfort. This medication is commonly used in situations involving certain distressing symptoms and relevant in contexts marked by increased discomfort or tension.

“It provides support that helps ease the overall symptom burden and offers symptomatic relief that helps patients cope more steadily.”

This medication contributes to easing the overall symptom load and may assist with maintaining functional stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.


Quick Fact

Quick Fact: Supports Easing Symptoms related to physical discomfort (is considered relevant in conditions where functional stability becomes affected).

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Furic?

Eligibility to use Furic (Febuxostat) is strictly defined by regulatory authorities and is based on age, existing medical conditions, and concurrent medication use.

Furic is primarily approved for adults (18 years and older) with hyperuricemia and a diagnosis of gout. Use is not recommended or not established for children and adolescents under 18 years of age. Older adults are eligible for standard use.


Absolute Contraindications

Furic must not be used in patients with an absolute contraindication, which includes a known history of hypersensitivity to febuxostat or any of its components. It is also contraindicated in patients currently receiving treatment with azathioprine or mercaptopurine.


Population-Specific Restrictions

Population Group Regulatory Status
Severe Hepatic Impairment (Child-Pugh Class C) Use is not recommended (insufficient data).
Ischaemic Heart Disease/Severe Heart Failure Use is not recommended.
Pregnancy and Lactation Use is not recommended.

Furic is not recommended for the treatment of asymptomatic hyperuricemia (without gout) or secondary hyperuricemia (e.g., organ transplant recipients). Patients with established cardiovascular disease may have conditional eligibility, as specified in regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information classifies several interactions, primarily based on the alteration of metabolic pathways. The most significant constraints involve medicinal products that are substrates for the Xanthine Oxidase (XO) enzyme.

Mandatory Restrictions and Prohibited Combinations

Co-administration with Azathioprine and Mercaptopurine is formally contraindicated. This restriction is due to Furic (Febuxostat) inhibiting the XO enzyme, which leads to severely increased plasma concentrations and associated toxicity risk from the co-administered drugs.

Pharmacokinetic Interaction Patterns

Interacting Substance Official Interaction Statement
Naproxen Coadministration increases the systemic exposure (AUC) of Furic (Febuxostat).
Apalutamide The systemic exposure of Furic (Febuxostat) is decreased due to Apalutamide increasing elimination.
Theophylline Metabolism is altered, specifically the formation of the 1-methylxanthine metabolite is inhibited, although no significant effect on the parent drug's plasma levels is documented.

Administration Requirements and Cautions

Furic may be taken without regard to the consumption of food or antacids, as no mandatory timing restrictions are required by the regulatory label. Caution regarding the interaction profile is officially noted for patients with severe hepatic impairment or severe renal impairment due to a lack of complete interaction data in these populations.

Mechanism of Action

Selective Blockade of the Uric Acid Synthesis Pathway

The drug's mechanism of action is mediated through the effective, non-purine selective inhibition of the enzyme Xanthine Oxidase (XO). The active molecule achieves this by binding reversibly to the enzyme's Molybdenum Pterin Center, neutralizing its catalytic function. This action is selective, targeting both the reduced (Xanthine Dehydrogenase, XDH) and oxidized (XO) forms of the enzyme to halt the terminal steps of the purine catabolism pathway.


Systemic Consequence: Reducing Circulating Urate

The physiological effect of the enzyme blockade is the resulting reduction in systemic uric acid production. By preventing the conversion of the purine precursors (hypoxanthine and xanthine) into uric acid, the mechanism causes a measurable and sustained fall in serum urate levels . The intermediate precursors are more water-soluble than uric acid, allowing them to be efficiently cleared and excreted from the body, thereby leading to a lower systemic quantity of the metabolite through metabolic regulation rather than by influencing renal clearance mechanisms.

Dosage and Administration Information

How Furic is Used

Furic (Febuxostat) is an oral tablet administered as part of a long-term plan for managing elevated urate levels. The standard approach to its use is based on achieving and maintaining a target level of serum uric acid.


Administration Guidelines

Feature Guideline
Route of Administration The medicine is administered orally as a tablet.
Dosing Schedule Treatment starts at 40 mg once daily. The dose may be increased to 80 mg once daily if the target urate level is not reached after two weeks; certain recommendations may permit an increase up to 120 mg once daily.
Timing and Food The tablet may be taken without regard to food or antacids.

Procedural Usage Structure

The usage protocol establishes a once-daily intake regimen. The initial dose is 40 mg, which is then adjusted based on blood test results to ensure consistent therapeutic activity. Treatment is generally not initiated during an acute gout flare; however, if a flare occurs while on therapy, the medicine is not to be discontinued as the flare is managed concurrently. A concurrent anti-flare regimen is typically utilized for up to six months following the start of treatment. Furthermore, for patients with severe kidney impairment, the daily dose is limited to 40 mg.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Furic

This section summarizes the published research and clinical trials that regulators reviewed for the evaluation of Furic (Febuxostat). This overview focuses on the types of studies conducted, the outcomes they measured, and areas of scientific uncertainty, without providing clinical advice or making claims about personal outcomes.


Evidence for Use in Managing Chronic Hyperuricemia and Gout

Furic has been studied as a urate-lowering therapy (ULT) in adult populations with chronic hyperuricemia—a long-term condition of high serum urate levels—specifically in the context of gout. Research has explored this use primarily through large-scale, controlled clinical trials.

Studies were conducted to measure changes in serum urate (sUA) concentration: specifically, the percentage of patients whose sUA level reached a target concentration over time. These trials also tracked related clinical events, such as the frequency of gout flares. In these controlled settings, data were collected on the number of patients whose sUA level was measured at the target concentration during the study period.


Research Focus on Long-Term Cardiovascular Outcomes

Regulators required extended, large-scale studies to explore the cardiovascular outcomes in comparison to allopurinol. This research involved major, long-term Randomized Controlled Trials (RCTs) designed specifically as cardiovascular outcomes trials.

These trials included adults with gout who had pre-existing or a high risk for Cardiovascular Disease (CVD). The principal outcome measured was the occurrence of a composite measure of major heart-related events (MACE). Findings from one large trial (CARES) reported patterns that included a numerically higher incidence of all-cause death and heart-related death in the Febuxostat group compared to the allopurinol group. However, a subsequent major trial (FAST) reported different findings for these specific mortality endpoints, observing no difference between the two groups during the long-term follow-up. This difference in findings between the two large-scale studies is a key area of discussion in the regulatory and scientific communities.


Areas of Research Uncertainty and Study Gaps

Research highlights several areas where certainty remains low or where evidence is limited. A major area of uncertainty is the discrepancy in findings between the two primary long-term cardiovascular outcomes trials regarding all-cause and cardiovascular death. Further limitations include the fact that long-term outcomes for efficacy (beyond the initial few years) are mainly derived from open-label studies, which were not controlled, meaning that comparative evidence is lacking over those extended periods. Findings describe group patterns but research does not determine whether an individual will respond or experience outcomes similarly.

Frequently Asked Questions (FAQ)

Common questions about Furic (FAQ)


Q: How quickly does Furic start to work?

A: Furic's purpose is to lower the level of uric acid in the blood (serum urate). Official studies show that this urate-lowering effect can often be measured as early as two weeks after starting the medicine. However, the overall therapeutic benefit is achieved over the long term as the medicine continues to control these levels.


Q: What is the average duration of treatment with Furic?

A: Regulatory documents describe Furic as a medicine intended for the long-term management of chronic hyperuricemia and gout. This indicates that, for most patients, treatment is expected to continue indefinitely to maintain the target level of uric acid in the blood.


Q: Can Furic interact with alcohol?

A: The official prescribing information for Furic does not contain a specific mandatory restriction or warning for the use of alcohol. However, official information notes that alcohol consumption may sometimes be a factor in the underlying condition being treated.


Q: Has there been much research on the long-term effects of Furic?

A: Yes. Regulatory bodies, such as the FDA and EMA, required and reviewed extended, large-scale studies on Furic. This research included long-term randomized controlled trials (RCTs) designed specifically to assess cardiovascular outcomes over several years.


Q: Is it okay to drink coffee while taking Furic?

A: Official regulatory labels state that Furic can be administered without regard to food or antacids. There are no specific restrictions on consuming coffee or caffeine mentioned in the official product information.


Q: Does Furic affect blood sugar levels?

A: The official regulatory label generally does not list changes in blood glucose (sugar) levels as a common or specific side effect. This type of information would typically be monitored during clinical trials and included in the product safety profile if found to be a frequent issue.


Q: What should I do if I forget to take a dose of Furic?

A: Official patient information sheets state that if a dose is missed, the patient should take it as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. It is required to resume the once-daily schedule and official guidelines advise not to take two doses at once.


Q: Does Furic interact with common over-the-counter pain relievers?

A: Official interaction tables generally do not cite a formal drug interaction with common over-the-counter pain relievers such as Acetaminophen or Ibuprofen. However, the pain reliever Naproxen is noted in regulatory information to increase Furic's systemic exposure.


Q: Are there any specific foods I should avoid while taking Furic?

A: No. The official regulatory documents explicitly state that Furic can be taken without regard to food. This indicates that there are no mandatory restrictions on avoiding specific foods while using the medicine.


Q: Is it common to feel tired when starting Furic?

A: Fatigue and somnolence (drowsiness) are reported in clinical studies as uncommon side effects, meaning they affect less than 1% of patients. If unexplained tiredness occurs, this is a factor that is generally recommended to be reviewed by a healthcare professional.


Q: Is Furic safe to take if I have liver problems?

A: Official warnings state that for patients with severe hepatic impairment (a serious form of liver disease), the use of Furic is not recommended due to a lack of complete data in that population. Official guidance indicates that use may be approached with specific consideration for patients with less severe liver problems.


Q: What happens if I stop taking Furic suddenly?

A: Patients are explicitly instructed in the official patient information not to stop taking the medicine unless directed to do so by a healthcare professional. Suddenly stopping may reverse the therapeutic goal, leading to the return of high uric acid levels.


Q: Are there different versions or strengths of Furic available?

A: Yes, Furic is typically approved and manufactured in two oral tablet strengths: 40 mg and 80 mg. The specific strength prescribed is based on the therapeutic goal of lowering uric acid to a target level.


Q: Is it true that Furic can change the color of my urine?

A: In some comprehensive safety documents, dark urine has been listed as an uncommon or rare side effect. If this occurs, it is generally recommended to be discussed with a healthcare professional.


Q: Are there any mental health side effects associated with Furic?

A: While rare, some regulatory side effect listings have included psychiatric events like anxiety or depression. These are noted as rare events in the comprehensive safety documentation reviewed by regulators.


Q: What are the restrictions on using Furic while breastfeeding?

A: Use is not recommended while breastfeeding. This is because official documents state it is currently unknown whether the medicine is excreted into human breast milk, which is a necessary safety consideration.


Q: Can I take Furic if I am pregnant or planning to be?

A: The medicine is not recommended for use during pregnancy. Official prescribing information states that it is not known if the drug may cause harm to the unborn child.


Q: Is it normal to have a slight headache on Furic?

A: Yes, headache is classified as a common side effect of Furic, meaning it was reported in clinical trials by 1% to less than 10% of patients. This is one of the most frequently observed effects.


Q: Does Furic make you more sensitive to the sun?

A: Some regulatory side effect listings for Furic include rare dermatological effects, such as increased sensitivity to light (photosensitivity). If this occurs, it is generally recommended to be discussed with a healthcare professional.


Q: What are the typical signs that Furic is working?

A: The primary sign that Furic is working correctly is the achievement and maintenance of the target serum uric acid (sUA) level, which is measured via a blood test. The therapeutic goal described in official documents is generally to maintain sUA levels below 6 mg/dL.


Q: Why is Furic sometimes prescribed for a short time only?

A: While Furic is primarily used for the long-term management of gout, it is also approved for managing high uric acid levels that occur with chemotherapy for certain blood cancers (tumor lysis syndrome risk). This specific use is generally shorter-term.


Q: Is there a generic version of Furic available?

A: Yes, major regulatory bodies, such as the FDA, have approved generic versions of the active ingredient, febuxostat, in both 40 mg and 80 mg tablet strengths.


Q: Why do some patients get a different dosage of Furic than others?

A: Dosage is personalized based on achieving the therapeutic goal. Adjustments from the starting dose are made depending on whether the patient reaches the target serum urate (sUA) level after a specified period. Furthermore, a different dose limit is required for patients with severe kidney impairment.


Q: How long after taking Furic can I safely drive?

A: Official warnings state that the medicine can cause side effects like dizziness, somnolence (drowsiness), or blurred vision. Patients are cautioned about driving or operating machinery until they are reasonably certain the medicine does not cause these effects for them.


Q: Is Furic used for conditions other than its main approved use?

A: Yes, in addition to its main use for chronic gout management, it is also approved in some regions for high uric acid levels that occur with chemotherapy for blood cancers, to prevent the risk of tumor lysis syndrome.


Q: Does Furic cause weight gain or loss?

A: Regulatory safety documentation has listed weight gain as a rare side effect in comprehensive safety reviews. If unexplained weight changes occur, regulatory information suggests they be reviewed by a health professional.


Q: Is Furic a drug with a high potential for dependence?

A: No. Furic is not classified as a controlled substance by major regulatory bodies in the US, Europe, or other major jurisdictions. This classification indicates a low potential for abuse or dependence.


Q: What studies support the use of Furic in children?

A: Official prescribing information consistently states that the safety and effectiveness of Furic have not been established in children and adolescents under 18 years of age. Therefore, its use is generally restricted to adults.


Q: Is it required to take Furic with food?

A: No. The medicine may be taken without regard to food or antacids. This means there is no mandatory requirement to take Furic with a meal or snack.


Q: Does the time of day matter when taking Furic?

A: The official prescribed regimen is to take the medicine once daily. Regulatory labels do not impose a mandatory specific time of day, but taking it at roughly the same time each day is generally accepted practice to help maintain consistent drug levels.


Q: What does the patient information leaflet say about overdose symptoms for Furic?

A: The patient information leaflet contains a general instruction to contact a doctor or poison control center immediately in case of accidental overdose or if too much medication is taken. This is a standard safety requirement for all prescription medications.

How should Furic be stored and disposed of?

Furic (febuxostat) tablets must be stored and disposed of according to official regulatory requirements to ensure product stability and prevent environmental harm.

Labeled Storage Conditions

Requirement Official Statement
Temperature Store at Controlled Room Temperature (20^circC to 25^circC or 68^circF to 77^circF) is the standard, with excursions permitted up to 30^circC. Some regional labels state no special storage temperature is required.
Container Keep the medicine in the original container and maintain the container tightly closed.
Child Safety Keep out of the sight and reach of children is a mandatory safety instruction.

Official Disposal Rules

Unused or expired Furic must not be released into the environment via household waste or wastewater. Disposal must be carried out according to local, regional, and national hazardous waste regulations. Patients are instructed to consult their pharmacist or medical institution for guidance on how to safely discard the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Furic found in:

A-Z Index: